Trial · NCT00098020
Podocyte Retinoids
NCT00098020, Phase 2, Completed, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); results first posted 2017-12-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Podocyte Retinoids. Trials, record NCT00098020. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00098020
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Podocyte Retinoids
- NCT number
- NCT00098020
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Conditions
- Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
- Interventions
- Isotretinoin
- First posted
- 2004-12-02
- Last updated
- 2017-12-13
- Results first posted
- 2017-12-13
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Proteinuria at Week 24 From Baseline | Baseline and Week 24 | Change of proteinuria at Week 24 compared to the baseline using protein/creatinine ratio (PCR) |
| Secondary | Number of Patients Who Are in Complete Remission (CR) or Partial Remission (PR) at 6 Months or at the End of One Year. | End of one year from baseline | Based on 24hour proteinuria, response outcomes are defined as CR (complete remission): \<0.3 g/g PR (partial remission): 50% fall from baseline and \<2.0 g/g |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Proteinuria at Week 24 From Baseline | Baseline and Week 24 | A total of 7 patients is analyzed due to 1 withdrawal. | g/g | MEAN |
| SECONDARY | Number of Patients Who Are in Complete Remission (CR) or Partial Remission (PR) at 6 Months or at the End of One Year. | End of one year from baseline | Seven out of 8 subjects who were treated with isotretinoin completed Week 24. One out of the 7 subjected who completed Week 24 did not complete the whole study. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Proteinuria at Week 24 From Baseline | Isotretinoin | Baseline | 8.42 | Standard Deviation 4.69 | g/g |
| Change in Proteinuria at Week 24 From Baseline | Isotretinoin | Week 24 | 7.67 | Standard Deviation 5.36 | g/g |
| Number of Patients Who Are in Complete Remission (CR) or Partial Remission (PR) at 6 Months or at the End of One Year. | Isotretinoin | 0 | Participants |
Source ClinicalTrials.gov
Participant flow4
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Isotretinoin | 12 | |
| Overall Study | Started Isotretinoin | Isotretinoin | 8 | |
| Overall Study | COMPLETED | Isotretinoin | 6 | |
| Overall Study | NOT COMPLETED | Isotretinoin | 6 |
Source ClinicalTrials.gov
Adverse events43
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Agitation | Nervous system disorders | Isotretinoin | 1 | 8 | 3 |
| other | Alanine aminotransferase increased | Renal and urinary disorders | Isotretinoin | 1 | 8 | 1 |
| other | Alopecia | Blood and lymphatic system disorders | Isotretinoin | 1 | 8 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Isotretinoin | 2 | 8 | 3 |
| other | Anorexia | Gastrointestinal disorders | Isotretinoin | 2 | 8 | 2 |
| other | Arthralgia (knee/ankle) | Immune system disorders | Isotretinoin | 1 | 8 | 1 |
| other | Ascites | Blood and lymphatic system disorders | Isotretinoin | 1 | 8 | 1 |
| other | Aspartate aminotransferase increased | Hepatobiliary disorders | Isotretinoin | 1 | 8 | 1 |
| other | Cholesterol high | Hepatobiliary disorders | Isotretinoin | 1 | 8 | 1 |
| other | Conduction disorder | General disorders | Isotretinoin | 1 | 8 | 1 |
1 to 10 of 43Source ClinicalTrials.gov
See all 43 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Isotretinoin | 0 | 8 |
| Total, other adverse events | Isotretinoin | 8 | 8 |
| Total, serious adverse events | Isotretinoin | 0 | 8 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00098020
GET https://conductscience.org/api/trials/v1/NCT00098020/events?page=2